Cargando…

Quantification of T Cell Binding Polyclonal Rabbit Anti-thymocyte Globulin in Human Plasma with Liquid Chromatography Tandem-Mass Spectrometry

The addition of rabbit anti-human thymocyte globulin (ATG) to the conditioning regimen prior to allogeneic hematopoietic cell transplantation has significantly reduced the risk of graft-versus-host disease (GvHD) and graft failure. However, ATG has a small therapeutic window. Overexposure of ATG pos...

Descripción completa

Detalles Bibliográficos
Autores principales: Amrani, Mohsin El, Admiraal, Rick, Willaert, Lobke, Ebskamp-van Raaij, Lysette J. C., Lacna, Amelia M., Hack, C. Erik, Huitema, Alwin D. R., Nierkens, Stefan, van Maarseveen, Erik M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005072/
https://www.ncbi.nlm.nih.gov/pubmed/32030538
http://dx.doi.org/10.1208/s12248-020-0419-6
_version_ 1783494854854049792
author Amrani, Mohsin El
Admiraal, Rick
Willaert, Lobke
Ebskamp-van Raaij, Lysette J. C.
Lacna, Amelia M.
Hack, C. Erik
Huitema, Alwin D. R.
Nierkens, Stefan
van Maarseveen, Erik M.
author_facet Amrani, Mohsin El
Admiraal, Rick
Willaert, Lobke
Ebskamp-van Raaij, Lysette J. C.
Lacna, Amelia M.
Hack, C. Erik
Huitema, Alwin D. R.
Nierkens, Stefan
van Maarseveen, Erik M.
author_sort Amrani, Mohsin El
collection PubMed
description The addition of rabbit anti-human thymocyte globulin (ATG) to the conditioning regimen prior to allogeneic hematopoietic cell transplantation has significantly reduced the risk of graft-versus-host disease (GvHD) and graft failure. However, ATG has a small therapeutic window. Overexposure of ATG post-HCT hampers T cell immune reconstitution and has been associated with increased relapse rates and viral reactivations, whereas underexposure has been associated with an increased incidence of GvHD, both of which lead to increased mortality. Therapeutic drug monitoring of T cell binding ATG plasma levels provides a means to optimize dosing for patients at high risk for graft failure to ensure timely T cell immune reconstitution and subsequently increase survival chances. This manuscript describes the first liquid chromatography tandem-mass spectrometry (LC-MS/MS) method to quantify the pharmacologically active fraction of polyclonal ATG in plasma. This was achieved through immunoaffinity purification of active ATG from plasma with Jurkat T cells. After the binding and washing, samples were eluted, denatured, and trypsin-digested. Signature peptides originating from the IgG constant chain were measured with LC-MS/MS. Critical method parameters were optimized, and the method was successfully validated following European Medicines Agency (EMA) guidelines. The method covered the therapeutic range of ATG and was validated at a lower limit of quantification (LLOQ) of 1 AU/mL with an overall CV and bias of 11.8% and − 2.5%, respectively. In conclusion, we developed a LC-MS/MS-based method to quantify active polyclonal rabbit ATG in human plasma. We suggest that this novel assay can be used to monitor and optimize dosing of ATG in clinical practice. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1208/s12248-020-0419-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7005072
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-70050722020-02-25 Quantification of T Cell Binding Polyclonal Rabbit Anti-thymocyte Globulin in Human Plasma with Liquid Chromatography Tandem-Mass Spectrometry Amrani, Mohsin El Admiraal, Rick Willaert, Lobke Ebskamp-van Raaij, Lysette J. C. Lacna, Amelia M. Hack, C. Erik Huitema, Alwin D. R. Nierkens, Stefan van Maarseveen, Erik M. AAPS J Research Article The addition of rabbit anti-human thymocyte globulin (ATG) to the conditioning regimen prior to allogeneic hematopoietic cell transplantation has significantly reduced the risk of graft-versus-host disease (GvHD) and graft failure. However, ATG has a small therapeutic window. Overexposure of ATG post-HCT hampers T cell immune reconstitution and has been associated with increased relapse rates and viral reactivations, whereas underexposure has been associated with an increased incidence of GvHD, both of which lead to increased mortality. Therapeutic drug monitoring of T cell binding ATG plasma levels provides a means to optimize dosing for patients at high risk for graft failure to ensure timely T cell immune reconstitution and subsequently increase survival chances. This manuscript describes the first liquid chromatography tandem-mass spectrometry (LC-MS/MS) method to quantify the pharmacologically active fraction of polyclonal ATG in plasma. This was achieved through immunoaffinity purification of active ATG from plasma with Jurkat T cells. After the binding and washing, samples were eluted, denatured, and trypsin-digested. Signature peptides originating from the IgG constant chain were measured with LC-MS/MS. Critical method parameters were optimized, and the method was successfully validated following European Medicines Agency (EMA) guidelines. The method covered the therapeutic range of ATG and was validated at a lower limit of quantification (LLOQ) of 1 AU/mL with an overall CV and bias of 11.8% and − 2.5%, respectively. In conclusion, we developed a LC-MS/MS-based method to quantify active polyclonal rabbit ATG in human plasma. We suggest that this novel assay can be used to monitor and optimize dosing of ATG in clinical practice. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1208/s12248-020-0419-6) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-02-06 /pmc/articles/PMC7005072/ /pubmed/32030538 http://dx.doi.org/10.1208/s12248-020-0419-6 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Amrani, Mohsin El
Admiraal, Rick
Willaert, Lobke
Ebskamp-van Raaij, Lysette J. C.
Lacna, Amelia M.
Hack, C. Erik
Huitema, Alwin D. R.
Nierkens, Stefan
van Maarseveen, Erik M.
Quantification of T Cell Binding Polyclonal Rabbit Anti-thymocyte Globulin in Human Plasma with Liquid Chromatography Tandem-Mass Spectrometry
title Quantification of T Cell Binding Polyclonal Rabbit Anti-thymocyte Globulin in Human Plasma with Liquid Chromatography Tandem-Mass Spectrometry
title_full Quantification of T Cell Binding Polyclonal Rabbit Anti-thymocyte Globulin in Human Plasma with Liquid Chromatography Tandem-Mass Spectrometry
title_fullStr Quantification of T Cell Binding Polyclonal Rabbit Anti-thymocyte Globulin in Human Plasma with Liquid Chromatography Tandem-Mass Spectrometry
title_full_unstemmed Quantification of T Cell Binding Polyclonal Rabbit Anti-thymocyte Globulin in Human Plasma with Liquid Chromatography Tandem-Mass Spectrometry
title_short Quantification of T Cell Binding Polyclonal Rabbit Anti-thymocyte Globulin in Human Plasma with Liquid Chromatography Tandem-Mass Spectrometry
title_sort quantification of t cell binding polyclonal rabbit anti-thymocyte globulin in human plasma with liquid chromatography tandem-mass spectrometry
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005072/
https://www.ncbi.nlm.nih.gov/pubmed/32030538
http://dx.doi.org/10.1208/s12248-020-0419-6
work_keys_str_mv AT amranimohsinel quantificationoftcellbindingpolyclonalrabbitantithymocyteglobulininhumanplasmawithliquidchromatographytandemmassspectrometry
AT admiraalrick quantificationoftcellbindingpolyclonalrabbitantithymocyteglobulininhumanplasmawithliquidchromatographytandemmassspectrometry
AT willaertlobke quantificationoftcellbindingpolyclonalrabbitantithymocyteglobulininhumanplasmawithliquidchromatographytandemmassspectrometry
AT ebskampvanraaijlysettejc quantificationoftcellbindingpolyclonalrabbitantithymocyteglobulininhumanplasmawithliquidchromatographytandemmassspectrometry
AT lacnaameliam quantificationoftcellbindingpolyclonalrabbitantithymocyteglobulininhumanplasmawithliquidchromatographytandemmassspectrometry
AT hackcerik quantificationoftcellbindingpolyclonalrabbitantithymocyteglobulininhumanplasmawithliquidchromatographytandemmassspectrometry
AT huitemaalwindr quantificationoftcellbindingpolyclonalrabbitantithymocyteglobulininhumanplasmawithliquidchromatographytandemmassspectrometry
AT nierkensstefan quantificationoftcellbindingpolyclonalrabbitantithymocyteglobulininhumanplasmawithliquidchromatographytandemmassspectrometry
AT vanmaarseveenerikm quantificationoftcellbindingpolyclonalrabbitantithymocyteglobulininhumanplasmawithliquidchromatographytandemmassspectrometry